Archive · 28 Nov 2025
Pharma Stocks in Focus: Zydus, Emcure, Bajaj Healthcare
Three Indian pharmaceutical companies are in the news today.
Zydus Lifesciences got permission from the US to sell a diabetes medicine.
Emcure Pharmaceuticals had a visit from tax officials who checked their offices.
Bajaj Healthcare has a new boss to help run the company.
These events might affect the companies' stock prices today.
Zydus Lifesciences received USFDA approval for Empagliflozin and Linagliptin tablets, a generic diabetes drug.
Emcure Pharmaceuticals underwent a GST Department search and inspection at its offices from November 24-26.
Bajaj Healthcare appointed Shreekumar Nair as its new Chief Operating Officer effective November 27, 2025.
Nair has over 40 years of experience in the pharmaceutical industry, previously working at Alembic and Glenmark.
Emcure cooperated fully with the GST Department during the inspection, providing all requested documents and information.
- Who
- Zydus Lifesciences, Emcure Pharmaceuticals, Bajaj Healthcare
- What
- Regulatory approval, GST inspection, COO appointment
- When
- November 27-28, 2025
- Where
- India, US (for Zydus)
- Why
- Business operations and regulatory compliance
- Zydus Lifesciences
- Received USFDA approval for generic diabetes drug
- Emcure Pharmaceuticals
- GST Department conducted search and inspection
- Bajaj Healthcare
- Appointed Shreekumar Nair as COO